Document Detail


Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression.
MedLine Citation:
PMID:  19500017     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
It is not fully elucidated whether patients who receive antiretroviral therapy (ART) can maintain continued CD4 count increases. Previous studies suggested a plateau 2-4 years after treatment initiation. We aimed to characterize the evolution of CD4 counts in HIV-infected individuals receiving long-term suppressive ART, by performing a retrospective study of patients who maintained viral suppression (HIV RNA <400 copies/ml) for > or =5 years. We used linear regression models to determine for each individual whether the CD4 count continued to increase or plateau. Furthermore, we estimated whether the slope of the CD4 count for each individual became zero, which we defined as the CD4 set-point. We assessed factors associated with continued CD4 count rise, reaching a CD4 set-point and time to the CD4 set-point. Fifty-nine patients were included. The median baseline CD4 count was 238 (IQR, 120-360) cells/microl and the median duration on ART was 7.6 (IQR, 5.9-9.3) years. On ART, CD4 count continued to increase in 37 subjects (63%). Significant predictors of continued CD4 count increase included a lower baseline log10 HIV RNA (OR, 0.35; 95% CI, 0.14-0.89; p=0.026) and a shorter duration on ART (OR, 0.65; 95% CI, 0.47-0.91; p=0.021). Twenty-four (41%) subjects reached a set-point after a median 4.3 (IQR 1.8-6.4) years on ART. A lower baseline CD4 percentage was associated with both a longer time to reach the CD4 set-point and a lower CD4 count at the CD4 set-point. These findings suggest that CD4 count may continue to increase in some patients after several years of ART. Our results point to an advantage to commencing ART at higher CD4+ T cell strata. These data should be considered when estimating the optimal time to initiate ART.
Authors:
Helen Byakwaga; John M Murray; Kathy Petoumenos; Anthony D Kelleher; Matthew G Law; Mark A Boyd; Sean Emery; Patrick W Mallon; David A Cooper
Related Documents :
19478647 - Treatment of spondylodiscitis in human immunodeficiency virus-infected patients: a comp...
8853737 - The international epidemiology of disseminated mycobacterium avium complex infection in...
22098767 - Hiv prevention in young people in sub-saharan africa: a systematic review.
15847717 - Sinusitis in hiv: microbiology and therapy.
2170237 - Hepatitis c viral cdna clones isolated from a healthy carrier donor implicated in post-...
19372777 - Acute hiv infection: it takes more than guts.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  AIDS research and human retroviruses     Volume:  25     ISSN:  1931-8405     ISO Abbreviation:  AIDS Res. Hum. Retroviruses     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-06-19     Completed Date:  2009-07-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8709376     Medline TA:  AIDS Res Hum Retroviruses     Country:  United States    
Other Details:
Languages:  eng     Pagination:  756-76     Citation Subset:  IM; X    
Affiliation:
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst, NSW 2010, Australia. hbyakwaga@nchecr.unsw.edu.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anti-HIV Agents / therapeutic use*
Antiretroviral Therapy, Highly Active*
CD4 Lymphocyte Count / trends
Female
HIV Infections / drug therapy*,  immunology*,  virology
HIV-1 / drug effects*
Humans
Male
Middle Aged
Retrospective Studies
Time Factors
Viral Load
Chemical
Reg. No./Substance:
0/Anti-HIV Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Detection of drug resistance-associated and background mutations in human immunodeficiency virus typ...
Next Document:  Deglycosylation or partial removal of HIV-1 CN54 gp140 V1/V2 domain enhances env-specific T cells.